The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Merus N.V. MRUS shares have jumped 29.9% over the past three months. The uptrend was fueled by encouraging interim results from a phase II study evaluating its bispecific antibody, petosemtamab ...

Exporting counterfeit medicines is a cruel business that robs ill people of any hope for relief. Cancer patients unknowingly using fake Keytruda would have no chance of improvement with their terminal ...

Freshfields is advising Merck on its $10bn acquisition of respiratory-focused pharmaceutical company Verona Pharma, in a ...

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

This is an audio transcript of the FT News Briefing podcast episode: ‘Big Pharma markets left in a ‘patent cliff’-hanger’ ...

The case was heard by US District Judge Ricardo S. Martinez, who said, “The issue here is the introduction of adulterated drugs to people who think they are getting lifesaving drugs… This activity has ...

We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha says as Glenmark ...

Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...